{"doi":"10.1136/jnnp.2009.197483","title":"Differential levels of  -synuclein,  -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease","abstract":null,"journal":"Journal of Neurology, Neurosurgery &amp; Psychiatry","year":2010,"id":639755,"datarank":7.008200683841127,"base_score":4.983606621708336,"endowment":4.983606621708336,"self_citation_contribution":0.7475409932562506,"citation_network_contribution":6.260659690584877,"self_endowment_contribution":0.7475409932562506,"citer_contribution":6.260659690584877,"corpus_percentile":null,"corpus_rank":null,"citation_count":145,"citer_count":137,"citers_with_citation_signal":123,"citers_with_endowment":123,"datacite_reuse_total":6,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1662385,"name":"T. Tokutake","orcid":null,"position":1,"is_corresponding":false},{"id":41300,"name":"A. Ishikawa","orcid":"0000-0002-3561-5633","position":2,"is_corresponding":false},{"id":1662386,"name":"T. Uchiyama","orcid":null,"position":3,"is_corresponding":false},{"id":1662387,"name":"T. Tokuda","orcid":null,"position":4,"is_corresponding":false},{"id":1662388,"name":"O. Onodera","orcid":null,"position":5,"is_corresponding":false},{"id":1662389,"name":"M. Nishizawa","orcid":null,"position":6,"is_corresponding":false},{"id":1662390,"name":"T. Ikeuchi","orcid":null,"position":7,"is_corresponding":false},{"id":1662384,"name":"K. Kasuga","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Differential levels of  -synuclein,  -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease","abstract":"BACKGROUND: The clinical diagnosis of dementia with Lewy bodies (DLB) is made on the basis of consensus criteria; however, the sensitivity of the criteria is relatively low. There are no generally accepted biomarkers to distinguish DLB from other dementias. Here the utility of quantification of alpha-synuclein, beta-amyloid42 (Abeta42) and tau in the CSF of patients with DLB, Alzheimer's disease (AD) and other dementias was examined. METHODS: 86 patients were divided into three age and sex matched groups: DLB (n=34), AD (n=31) and other dementias (n=21). Two patients with alpha-synuclein gene (SNCA) duplication were also examined. Abeta and tau were quantified using an ELISA kit. A modified sandwich ELISA was developed which enables the sensitive quantification of CSF alpha-synuclein. RESULTS: Total and phosphorylated tau levels as well as Abeta40/42 and tau/Abeta42 ratios were significantly higher in AD patients than in patients with DLB (p<0.01) and other dementias (p<0.01). CSF alpha-synuclein levels in DLB patients were significantly lower than those in patients with AD (p<0.05) and other dementias (p<0.01). CSF alpha-synuclein level correlated with the Abeta42 level in DLB patients (p=0.01, r=0.43). Two patients with SNCA duplication exhibited relatively low levels of CSF alpha-synuclein. CONCLUSIONS: The study suggests that reduced levels of CSF alpha-synuclein in DLB may reflect the accumulation of alpha-synuclein with Lewy pathology in the brain and that quantification of CSF alpha-synuclein helps in the differentiation of DLB from AD and other dementias in combination with Abeta42 and tau analysis.","is_dataset_classified":null,"base_score":4.983606621708336,"endowment":4.983606621708336,"datacite_reuse_total":6,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"20522869","pmcid":null,"openalex_id":"https://openalex.org/W2100437146","authors":[],"funders":[],"total_grants":0,"fwci":9.1749,"citation_percentile":0.98642429,"influential_citations":8,"citation_trend":[{"year":2012,"count":14},{"year":2013,"count":19},{"year":2014,"count":12},{"year":2015,"count":11},{"year":2016,"count":8},{"year":2017,"count":3},{"year":2018,"count":8},{"year":2019,"count":10},{"year":2020,"count":5},{"year":2021,"count":8},{"year":2022,"count":8},{"year":2023,"count":4},{"year":2024,"count":10},{"year":2025,"count":3}],"oa_status":"closed","license":null,"oa_locations":[{"url":"https://syndication.highwire.org/content/doi/10.1136/jnnp.2009.197483","host_type":"publisher"},{"url":"https://doi.org/10.1136/jnnp.2009.197483","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/20522869","host_type":"repository"}],"fields_of_study":["Dementia and Cognitive Impairment Research","Parkinson's Disease Mechanisms and Treatments","Alzheimer's disease research and treatments","Psychology","Medicine","Aged","Alzheimer Disease","Amyloid beta-Peptides","Enzyme-Linked Immunosorbent Assay","Female","Humans","Lewy Body Disease","Male","Peptide Fragments","Phenotype","alpha-Synuclein","tau Proteins"],"mesh_terms":["Aged","Alzheimer Disease","Enzyme-Linked Immunosorbent Assay","Female","Humans","Male","Peptide Fragments","Phenotype","Amyloid beta-Peptides","tau Proteins","Lewy Body Disease","alpha-Synuclein"],"keywords":["Dementia with Lewy bodies","Alpha-synuclein","Dementia","Cerebrospinal fluid","Differential diagnosis","Internal medicine","Medicine","Parkinson's disease","Pathology","Alzheimer's disease","Lewy body","Degenerative disease","Disease","Gastroenterology"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[{"doi":"10.6084/m9.figshare.20619888.v1","title":"Additional file 1 of Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.20619888","title":"Additional file 1 of Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer’s disease","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25792757.v1","title":"Additional file 1 of Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25792757","title":"Additional file 1 of Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25792881.v1","title":"Additional file 2 of Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.25792881","title":"Additional file 2 of Cerebrospinal fluid α-synuclein adds the risk of cognitive decline and is associated with tau pathology among non-demented older adults","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-07T01:30:01.165790Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}